CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 30 enrolled
Drug / intervention
Lenvatinib and Gefitinibdrug
Likely dose
Lenvatinib and Gefitinib 125mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04642547
NCT04642547N/ACompleted
CompareCT.gov

A Prospective Clinical Study of Lenvatinib Combined With Gefitinib in the Treatment of Lenvatinib-resistant Hepatocellular Carcinoma

RenJi Hospital·interventional·Posted Nov 24, 2020·Updated Aug 1, 2023

In Brief

A clinical study evaluating Lenvatinib and Gefitinib for Hepatocellular Carcinoma and Molecular Targeted Therapy. Completed, enrolled 30 participants across 1 site.

Detailed Summary

This is a prospective clinical study aiming to tests the safety and efficacy of lenvatinib in combination with gefitinib in people with lenvatinib resistant hepatocellular carcinoma. This study will help find out if lenvatinib and gefitinib is a safe and useful combination for treating patients with lenvatinib resistant hepatocellular carcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHepatocellular Carcinoma, Molecular Targeted Therapy
CountriesChina
Collaborators--

Timeline

N/ACompletedFinished
202120222023202420252026
First PostedNov 24, 2020
Enrollment StartDec 2, 2020
Primary CompletionMar 31, 2023
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 5.6 years ago

Interventions

Lenvatinib and Gefitinibdrug

First week: Gefitinib: 125mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight \> 60Kg), oral. One week later: Gefitinib: 250mg/day, oral; Lenvatinib: 8mg/day (weight ≤ 60Kg) or 12mg/day (weight \> 60Kg), oral.